Drug combinations could become firstline treatment for metastatic kidney cancer

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

More From BioPortfolio on "Drug combinations could become first-line treatment for metastatic kidney cancer"